Atherosclerosis Drugs Market Report 2025

The atherosclerosis drugs market size has grown steadily in recent years. It will grow from $49.89 billion in 2024 to $51.42 billion in 2025 at a compound annual growth rate (CAGR) of 3.1%. The growth in the historic period can be attributed to cholesterol management, blood pressure control, smoking cessation programs, research and development, diagnostic advancements.

The atherosclerosis drugs market size is expected to see steady growth in the next few years. It will grow to $59.38 billion in 2029 at a compound annual growth rate (CAGR) of 3.7%. The growth in the forecast period can be attributed to emerging therapies, precision medicine, immunotherapy and inflammation, innovations in lipid management, regulatory support. Major trends in the forecast period include biologic therapies, gene editing and gene therapy, combination therapies, personalized treatment approaches, telemedicine and remote monitoring.

The increasing prevalence of cardiovascular diseases is anticipated to drive the growth of the atherosclerosis drug market in the future. Cardiovascular diseases encompass all conditions that impact the heart and blood vessels, while atherosclerosis specifically involves the accumulation of fats, cholesterol, and other substances along artery walls. This plaque buildup in the arteries leads to cardiovascular issues, including coronary heart disease and stroke. Atherosclerosis drugs are administered to manage cardiovascular diseases by reducing the risk of complications and addressing underlying factors such as high cholesterol levels and blood clot formation. For instance, in September 2024, data released by the Minnesota Department of Health, a US-based state health agency, indicated that around 30% of adults in Minnesota reported high blood pressure in 2023, affecting nearly 1.4 million individuals. Additionally, hypertensive diseases were the primary or contributing cause of death for 14,225 residents in 2022, accounting for nearly 28% of all deaths in the state. Consequently, the rising prevalence of cardiovascular diseases will propel the atherosclerosis drug market.

The increasing aging population is anticipated to drive the growth of the atherosclerosis drug market in the coming years. An aging population refers to a demographic trend marked by a substantial rise in the proportion or number of elderly individuals within a society. Atherosclerosis drugs are essential for the elderly, as they address heightened cardiovascular risks and play a critical role in prevention, management, and treatment to support overall health. For example, in January 2023, the United Nations Department of Economic and Social Affairs (UN DESA), a U.S.-based department of the UN Secretariat, projected that the global population aged 65 and older will more than double, increasing from 761 million in 2021 to 1.6 billion by 2050. Thus, the expanding aging population is driving the growth of the atherosclerosis drug market.

Product innovation is a prominent trend gaining momentum in the atherosclerosis drugs market. Leading companies in the market are developing innovative drugs and obtaining approvals to maintain their competitive edge. For example, in March 2024, Novo Nordisk A/S, a Denmark-based healthcare company, announced the approval of Wegovy (semaglutide) for reducing cardiovascular risk in individuals with overweight or obesity. This is the first weight loss medication approved to lower the risk of major cardiovascular events in adults with obesity or overweight and established cardiovascular disease, offering a new therapeutic option for this high-risk group. This dual functionality not only supports obesity management but also helps prevent serious cardiovascular complications, potentially enhancing patient outcomes and longevity.

Leading companies in the atherosclerosis drugs market are developing anti-inflammatory drugs to boost profitability and market share. Anti-inflammatory drugs for atherosclerosis aim to reduce inflammation linked to plaque buildup in arteries, a hallmark of the disease. For instance, in June 2023, AGEPHA Pharma, a Europe-based medical product manufacturer, launched LODOCO. LODOCO (colchicine, 0.5 mg tablet) received approval from the U.S. FDA as the first anti-inflammatory atheroprotective treatment for cardiovascular care. The drug effectively reduces the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults with atherosclerotic disease or multiple cardiovascular risk factors. By targeting residual inflammation, a critical factor in atherosclerotic cardiovascular disease (ASCVD), LODOCO can be used independently or alongside cholesterol-lowering medications, marking a significant advancement in cardiovascular treatment.

In April 2023, Chiesi Farmaceutici S.p.A., an Italian pharmaceutical company, completed the acquisition of Amryt Pharma plc for an approximate sum of $1.25 billion. This strategic move aims to expand Chiesi Farmaceutici S.p.A.'s rare disease portfolio, gain access to Amryt's pipeline of developmental candidates, and establish a presence in the US market. Amryt Pharma plc, based in Ireland, specializes in the development of atherosclerosis drugs for the treatment of rare diseases, including atherosclerosis and generalized lipodystrophies.

Major companies operating in the atherosclerosis drugs market include Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co.Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., Kowa Pharmaceuticals America Inc., Anthera Pharmaceuticals Inc.

North America was the largest region in the atherosclerosis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atherosclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the atherosclerosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Atherosclerosis drugs are medications employed for the management and treatment of atherosclerosis, a condition characterized by the accumulation of plaque in the arteries. The objectives of drug treatment for atherosclerosis include reducing plaque formation, slowing its progression, and addressing risk factors associated with the development of atherosclerosis.

The primary categories of atherosclerosis drugs encompass anti-platelet medications, fibric acid and omega-3 fatty acid derivatives, angiotensin-covering enzyme (ACE) inhibitors, diuretics, cholesterol-lowering medications, beta-blockers, calcium channel blockers, and other related medications. Antiplatelet medications are drugs that hinder the formation of blood clots by impeding the aggregation of platelets, which are small cell fragments in the blood. These drugs can be administered orally or through injections and are primarily dispensed through various channels, including hospital pharmacies, online pharmacies, retail pharmacies, and others.

The atherosclerosis drugs market research report is one of a series of new reports that provides atherosclerosis drugs market statistics, including atherosclerosis drugs industry global market size, regional shares, competitors with an atherosclerosis drugs market share, detailed atherosclerosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the atherosclerosis drugs industry. This atherosclerosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The atherosclerosis drugs market consists of sales of statins, rosuvastatin, atorvastatin, fibrates, bile acid sequestrants, nitrates, ezetimibe, and blood pressure medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.